Details of the Drug

General Information of Drug (ID: DML53ZJ)

Drug Name
Mirtazapine
Synonyms
Avanza; Axit; Azamianserin; Mepirzapin; Mepirzepine; Mirtabene; Mirtaz; Mirtazapina; Mirtazapinum; Mirtazepine; Mirtazipine; Mirtazon; Norset; Promyrtil; Remergil; Remergon; Remeron; Rexer; Zispin; Celltech brand of mirtazapine; Mundogen brand of mirtazapine; Organon brand of mirtazapine; Remeron SolTab; ORG 3770; Afloyan (TN); Alphamirt (TN); Alphazagen (TN); Amirel (TN); Arintapin (TN); Arintapina (TN); Avanza (TN); Axit (TN); Bexzis (TN); Calixta (TN); Ciblex (TN); Combar (TN); Comenter (TN); Divaril (TN); Esprital (TN); Finmirtaza (TN); Finpharma (TN); Finscope (TN); Genamirt (TN); Hexazipin (TN); Loxozapin (TN); ME-2040; Medizapin (TN); Miralix (TN); Mirap (TN); Mirazep (TN); Miro (TN); Miron (TN); Mirta (TN); Mirtabene (TN); Mirtachem (TN); Mirtacur (TN); Mirtadepi (TN); Mirtagamma (TN); Mirtal (TN); Mirtalich (TN); Mirtalphagen (TN); Mirtamed (TN); Mirtamerck (TN); Mirtapax (TN); Mirtapharm (TN); Mirtapin(TN); Mirtaratio (TN); Mirtaril (TN); Mirtaron (TN); Mirtascope (TN); Mirtasole (TN); Mirtastad (TN); Mirtastada (TN); Mirtatifi (TN); Mirtatsapiini (TN); Mirtawin (TN); Mirtaz (TN); Mirtazapin (TN);Mirtazapina (TN); Mirtazapina [INN-Spanish]; Mirtazapinum [INN-Latin]; Mirtazelon (TN); Mirtazen (TN); Mirtazep (TN); Mirtazepin (TN); Mirtazon (TN); Mirtazza (TN); Mirtel (TN); Mirtoral (TN); Mirzagen (TN); Mirzalux (TN); Mirzaten (TN); Mitrazen (TN); Mizapin (TN); Mizapin Sol (TN); Norset (TN); Noxibel (TN); Pharmasole (TN); Pharmazepine (TN); Promyrtil (TN); Remergil (TN); Remergon (TN); Remeron (TN); Remeron SolTab (TN); Remirta (TN); Rexer (TN); SolTab (TN); Tarzapine (TN); Tazamel (TN); Tazapin (TN); Tazascope (TN); Tirzamed (TN); Valdren (TN); Vastat (TN); Zapex (TN); Zicomber (TN); Zismirt (TN); Zispin (TN); Zispin SolTab (TN); Zuleptan (TN); Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirzaten Q-Tab (TN); Zistap. (TN); Mirtazapine (JAN/USAN/INN); (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; (N-methyl-11C)mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; 6-Azamianserin
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 265.35
Logarithm of the Partition Coefficient (xlogp) 3.3
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance
The total body clearance of drug is 1 L/h [3]
Elimination
This drug is mainly excreted by the kidney. It is 75% eliminated in the urine and 15% eliminated in the feces [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 - 40 hours []
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.82634 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.15% [5]
Vd
The volume of distribution (Vd) of drug is 107 +/- 42 L [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.5 mg/mL [2]
Chemical Identifiers
Formula
C17H19N3
IUPAC Name
5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
Canonical SMILES
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
InChI
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
InChIKey
RONZAEMNMFQXRA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4205
ChEBI ID
CHEBI:6950
CAS Number
85650-52-8
DrugBank ID
DB00370
TTD ID
D05ZIK
INTEDE ID
DR1098
ACDINA ID
D00439
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Antagonist [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [8]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [9]
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Gene/Protein Processing [11]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Gene/Protein Processing [12]
Solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4) OTJZG0LD GLUT4_HUMAN Gene/Protein Processing [13]
Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5) OTZNYEKF GTR5_HUMAN Gene/Protein Processing [13]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 2C receptor (HTR2C) DTT HTR2C 1.02E-02 -0.45 -0.37
5-HT 2C receptor (HTR2C) DTT HTR2C 2.27E-01 0.27 0.6
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.94E-01 -1.03E-01 -3.08E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 7.37E-02 9.49E-02 8.07E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 6.73E-02 6.49E-02 3.07E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 6.45E-01 2.07E-02 1.74E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 2.59E-01 6.29E-02 3.14E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 4.84E-01 -8.38E-02 -8.46E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 8.99E-01 -6.93E-03 -1.36E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 9.21E-01 7.31E-03 6.10E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.66E-01 4.25E-02 1.20E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.75E-01 5.15E-02 3.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mirtazapine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Aprepitant DM053KT Moderate Decreased metabolism of Mirtazapine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [14]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Mirtazapine and Sertraline. Depression [6A70-6A7Z] [15]
Trimipramine DM1SC8M Major Additive serotonergic effects by the combination of Mirtazapine and Trimipramine. Depression [6A70-6A7Z] [15]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Mirtazapine and Cyclobenzaprine. Depression [6A70-6A7Z] [15]
Imipramine DM2NUH3 Major Additive serotonergic effects by the combination of Mirtazapine and Imipramine. Depression [6A70-6A7Z] [15]
Fluoxetine DM3PD2C Major Additive serotonergic effects by the combination of Mirtazapine and Fluoxetine. Depression [6A70-6A7Z] [15]
Nortriptyline DM4KDYJ Major Additive serotonergic effects by the combination of Mirtazapine and Nortriptyline. Depression [6A70-6A7Z] [15]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Mirtazapine and Vilazodone. Depression [6A70-6A7Z] [15]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Mirtazapine and Nefazodone. Depression [6A70-6A7Z] [15]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Mirtazapine and Paroxetine. Depression [6A70-6A7Z] [15]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Mirtazapine and Selegiline. Depression [6A70-6A7Z] [16]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Mirtazapine and Vortioxetine. Depression [6A70-6A7Z] [15]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Mirtazapine and Duloxetine. Depression [6A70-6A7Z] [15]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Mirtazapine and Isocarboxazid. Depression [6A70-6A7Z] [16]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Mirtazapine and Milnacipran. Depression [6A70-6A7Z] [15]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Mirtazapine and Escitalopram. Depression [6A70-6A7Z] [17]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Mirtazapine and Tranylcypromine. Depression [6A70-6A7Z] [16]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Mirtazapine and Desvenlafaxine. Depression [6A70-6A7Z] [15]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Mirtazapine and Phenelzine. Depression [6A70-6A7Z] [16]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Mirtazapine and Clomipramine. Depression [6A70-6A7Z] [15]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Mirtazapine and Trazodone. Depression [6A70-6A7Z] [15]
Amoxapine DMKITQE Major Additive serotonergic effects by the combination of Mirtazapine and Amoxapine. Depression [6A70-6A7Z] [15]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Mirtazapine and Doxepin. Depression [6A70-6A7Z] [15]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Mirtazapine and Maprotiline. Depression [6A70-6A7Z] [15]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Mirtazapine and Esketamine. Depression [6A70-6A7Z] [18]
⏷ Show the Full List of 25 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Mirtazapine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Mirtazapine and Methylene blue. Acquired methaemoglobinaemia [3A93] [19]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Ivosidenib. Acute myeloid leukaemia [2A60] [20]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Idarubicin. Acute myeloid leukaemia [2A60] [21]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Daunorubicin. Acute myeloid leukaemia [2A60] [21]
Arn-509 DMT81LZ Moderate Increased metabolism of Mirtazapine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [21]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Gilteritinib. Acute myeloid leukaemia [2A60] [22]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Oliceridine. Acute pain [MG31] [21]
Mitotane DMU1GX0 Moderate Increased metabolism of Mirtazapine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [21]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Tacrine. Alzheimer disease [8A20] [23]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Galantamine. Alzheimer disease [8A20] [23]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Rivastigmine. Alzheimer disease [8A20] [23]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Mirtazapine and Metronidazole. Amoebiasis [1A36] [18]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Ivabradine. Angina pectoris [BA40] [24]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Bepridil. Angina pectoris [BA40] [23]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Dronedarone. Angina pectoris [BA40] [23]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Mirtazapine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [25]
Buspirone DMBS632 Major Additive serotonergic effects by the combination of Mirtazapine and Buspirone. Anxiety disorder [6B00-6B0Z] [15]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Cilostazol. Arterial occlusive disease [BD40] [21]
Voriconazole DMAOL2S Moderate Decreased metabolism of Mirtazapine caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [14]
Posaconazole DMUL5EW Moderate Decreased metabolism of Mirtazapine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [14]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Levalbuterol. Asthma [CA23] [26]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Terbutaline. Asthma [CA23] [27]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Pirbuterol. Asthma [CA23] [27]
Zileuton DMVRIC2 Moderate Decreased metabolism of Mirtazapine caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [14]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [24]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Mirtazapine and Desipramine. Attention deficit hyperactivity disorder [6A05] [15]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Mirtazapine caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [28]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Ofloxacin. Bacterial infection [1A00-1C4Z] [21]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Mirtazapine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Mirtazapine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Mirtazapine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Mirtazapine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [23]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Mirtazapine and Linezolid. Bacterial infection [1A00-1C4Z] [29]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Levofloxacin. Bacterial infection [1A00-1C4Z] [21]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [21]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Mirtazapine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Loperamide. Bowel habit change [ME05] [30]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Eribulin. Breast cancer [2C60-2C6Y] [21]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Lapatinib. Breast cancer [2C60-2C6Y] [21]
Tucatinib DMBESUA Moderate Decreased metabolism of Mirtazapine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [14]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Tamoxifen. Breast cancer [2C60-2C6Y] [21]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Mirtazapine and Toremifene. Breast cancer [2C60-2C6Y] [23]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Bosutinib. Breast cancer [2C60-2C6Y] [21]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Mirtazapine and Sotalol. Cardiac arrhythmia [BC9Z] [23]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [31]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [27]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [26]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [27]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [27]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [27]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Mirtazapine caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [21]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Mirtazapine and Dihydrocodeine. Chronic pain [MG30] [32]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Mirtazapine and Levomilnacipran. Chronic pain [MG30] [15]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Oxaliplatin. Colorectal cancer [2B91] [21]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Isoproterenol. Conduction disorder [BC63] [26]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Mirtazapine and Olopatadine. Conjunctiva disorder [9A60] [33]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Halothane. Corneal disease [9A76-9A78] [21]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Propofol. Corneal disease [9A76-9A78] [34]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Sevoflurane. Corneal disease [9A76-9A78] [21]
Alfentanil DMVO0UB Major Additive serotonergic effects by the combination of Mirtazapine and Alfentanil. Corneal disease [9A76-9A78] [15]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Mirtazapine and Remifentanil. Corneal disease [9A76-9A78] [15]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Probucol. Coronary atherosclerosis [BA80] [21]
Dextromethorphan DMUDJZM Major Additive serotonergic effects by the combination of Mirtazapine and Dextromethorphan. Cough [MD12] [15]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Mirtazapine and Mifepristone. Cushing syndrome [5A70] [23]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Mirtazapine and Pasireotide. Cushing syndrome [5A70] [23]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Mirtazapine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [14]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Mirtazapine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [35]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Mirtazapine and Ethanol. Cystitis [GC00] [33]
MK-8228 DMOB58Q Moderate Decreased metabolism of Mirtazapine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [14]
Griseofulvin DMK54YG Moderate Increased metabolism of Mirtazapine caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [21]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Mirtazapine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [36]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [23]
Fenfluramine DM0762O Major Additive serotonergic effects by the combination of Mirtazapine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [15]
Primidone DM0WX6I Moderate Increased metabolism of Mirtazapine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Cenobamate DM8KLU9 Moderate Increased metabolism of Mirtazapine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Stiripentol DMMSDOY Moderate Decreased metabolism of Mirtazapine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Mirtazapine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Phenobarbital DMXZOCG Moderate Increased metabolism of Mirtazapine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Carbamazepine DMZOLBI Moderate Increased metabolism of Mirtazapine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Tazemetostat DMWP1BH Moderate Increased metabolism of Mirtazapine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [21]
Mirabegron DMS1GYT Moderate Decreased metabolism of Mirtazapine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [14]
Itraconazole DMCR1MV Moderate Decreased metabolism of Mirtazapine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Pentamidine. Fungal infection [1F29-1F2F] [21]
Terbinafine DMI6HUW Moderate Decreased metabolism of Mirtazapine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Mirtazapine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Cimetidine DMH61ZB Moderate Decreased metabolism of Mirtazapine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [14]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Mirtazapine and Cisapride. Gastro-oesophageal reflux disease [DA22] [23]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [21]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Mirtazapine and Brimonidine. Glaucoma [9C61] [37]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Mirtazapine caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [21]
Ergotamine DMKR3C5 Major Additive serotonergic effects by the combination of Mirtazapine and Ergotamine. Headache [8A80-8A84] [15]
Boceprevir DMBSHMF Moderate Decreased metabolism of Mirtazapine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [14]
Telaprevir DMMRV29 Moderate Decreased metabolism of Mirtazapine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [14]
Rifampin DMA8J1G Moderate Increased metabolism of Mirtazapine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [35]
Rifapentine DMCHV4I Moderate Increased metabolism of Mirtazapine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [21]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Mirtazapine and Procarbazine. Hodgkin lymphoma [2B30] [16]
Delavirdine DM3NF5G Moderate Decreased metabolism of Mirtazapine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Mirtazapine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Mirtazapine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Mirtazapine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [38]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Mirtazapine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [39]
Etravirine DMGV8QU Moderate Increased metabolism of Mirtazapine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [21]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Mirtazapine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Darunavir DMN3GCH Moderate Decreased metabolism of Mirtazapine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Atazanavir DMSYRBX Moderate Decreased metabolism of Mirtazapine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Ritonavir DMU764S Moderate Decreased metabolism of Mirtazapine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Verapamil DMA7PEW Moderate Decreased metabolism of Mirtazapine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [14]
Conivaptan DM1V329 Moderate Decreased metabolism of Mirtazapine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [14]
Givosiran DM5PFIJ Moderate Decreased metabolism of Mirtazapine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [14]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Mirtazapine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [14]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Polyethylene glycol. Irritable bowel syndrome [DD91] [23]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Phenolphthalein. Irritable bowel syndrome [DD91] [23]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Mirtazapine and Crizotinib. Lung cancer [2C25] [40]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Mirtazapine and Porfimer Sodium. Lung cancer [2C25] [41]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Mirtazapine and Ceritinib. Lung cancer [2C25] [23]
PF-06463922 DMKM7EW Moderate Increased metabolism of Mirtazapine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [21]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Mirtazapine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [14]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Mirtazapine and Osimertinib. Lung cancer [2C25] [42]
Capmatinib DMYCXKL Moderate Decreased metabolism of Mirtazapine caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [14]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Mirtazapine and Selpercatinib. Lung cancer [2C25] [24]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Mirtazapine and Lumefantrine. Malaria [1F40-1F45] [18]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Mirtazapine and Halofantrine. Malaria [1F40-1F45] [43]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Mirtazapine and Chloroquine. Malaria [1F40-1F45] [44]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Mirtazapine and Hydroxychloroquine. Malaria [1F40-1F45] [44]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Quinine. Malaria [1F40-1F45] [21]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Primaquine. Malaria [1F40-1F45] [21]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [24]
Idelalisib DM602WT Moderate Decreased metabolism of Mirtazapine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [14]
IPI-145 DMWA24P Moderate Decreased metabolism of Mirtazapine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [14]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [45]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Vemurafenib. Melanoma [2C30] [23]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and LGX818. Melanoma [2C30] [46]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Mirtazapine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [24]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Mirtazapine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [47]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Mirtazapine and Almogran. Migraine [8A80] [15]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Mirtazapine and Frovatriptan. Migraine [8A80] [15]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Mirtazapine and Rizatriptan. Migraine [8A80] [15]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Mirtazapine and Naratriptan. Migraine [8A80] [15]
Sumatriptan DMVYXR8 Major Additive serotonergic effects by the combination of Mirtazapine and Sumatriptan. Migraine [8A80] [15]
Exjade DMHPRWG Moderate Decreased metabolism of Mirtazapine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [14]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Mirtazapine and Flibanserin. Mood disorder [6A60-6E23] [48]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Mirtazapine and Thalidomide. Multiple myeloma [2A83] [49]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Siponimod. Multiple sclerosis [8A40] [18]
Rifabutin DM1YBHK Moderate Increased metabolism of Mirtazapine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [21]
Methoxsalen DME8FZ9 Moderate Decreased metabolism of Mirtazapine caused by Methoxsalen mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [14]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Romidepsin. Mycosis fungoides [2B01] [21]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Mirtazapine and Nilotinib. Myeloproliferative neoplasm [2A20] [23]
Imatinib DM7RJXL Moderate Decreased metabolism of Mirtazapine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [14]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Dasatinib. Myeloproliferative neoplasm [2A20] [21]
Modafinil DMYILBE Moderate Increased metabolism of Mirtazapine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [21]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Droperidol. Nausea/vomiting [MD90] [23]
Rolapitant DM8XP26 Moderate Decreased metabolism of Mirtazapine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [14]
Palonosetron DMBHMOX Major Additive serotonergic effects by the combination of Mirtazapine and Palonosetron. Nausea/vomiting [MD90] [23]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Mirtazapine and Granisetron. Nausea/vomiting [MD90] [23]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Mirtazapine and Dolasetron. Nausea/vomiting [MD90] [23]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Mirtazapine and Ondansetron. Nausea/vomiting [MD90] [23]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Mirtazapine and Bupropion. Nicotine use disorder [6C4A] [50]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Entrectinib. Non-small cell lung cancer [2C25] [18]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Mirtazapine and Sibutramine. Obesity [5B80-5B81] [51]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Mirtazapine and Lorcaserin. Obesity [5B80-5B81] [52]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Mirtazapine and Dexfenfluramine. Obesity [5B80-5B81] [15]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Levomethadyl Acetate. Opioid use disorder [6C43] [24]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Lofexidine. Opioid use disorder [6C43] [23]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Mirtazapine and Apraclonidine. Optic nerve disorder [9C40] [37]
Olaparib DM8QB1D Moderate Increased metabolism of Mirtazapine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [18]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Rucaparib. Ovarian cancer [2C73] [21]
Pentazocine DM1XBHS Major Additive serotonergic effects by the combination of Mirtazapine and Pentazocine. Pain [MG30-MG3Z] [15]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Mirtazapine and Oxymorphone. Pain [MG30-MG3Z] [32]
Levorphanol DMGS80V Moderate Additive serotonergic effects by the combination of Mirtazapine and Levorphanol. Pain [MG30-MG3Z] [32]
Nalbuphine DMOSQGU Moderate Additive serotonergic effects by the combination of Mirtazapine and Nalbuphine. Pain [MG30-MG3Z] [32]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Mirtazapine and Buprenorphine. Pain [MG30-MG3Z] [32]
Hydrocodone DMQ2JO5 Moderate Additive serotonergic effects by the combination of Mirtazapine and Hydrocodone. Pain [MG30-MG3Z] [32]
Meperidine DMX4GND Major Additive serotonergic effects by the combination of Mirtazapine and Meperidine. Pain [MG30-MG3Z] [15]
Oxycodone DMXLKHV Moderate Additive serotonergic effects by the combination of Mirtazapine and Oxycodone. Pain [MG30-MG3Z] [32]
Thiabendazole DM7YCK3 Moderate Decreased metabolism of Mirtazapine caused by Thiabendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [14]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Triclabendazole. Parasitic worm infestation [1F90] [21]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Mirtazapine and Safinamide. Parkinsonism [8A00] [16]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Mirtazapine and Rasagiline. Parkinsonism [8A00] [16]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Pimavanserin. Parkinsonism [8A00] [53]
Abametapir DM2RX0I Moderate Decreased metabolism of Mirtazapine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [54]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Mirtazapine and Lindane. Pediculosis [1G00] [55]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Famotidine. Peptic ulcer [DA61] [18]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Mirtazapine and Macimorelin. Pituitary gland disorder [5A60-5A61] [56]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Lefamulin. Pneumonia [CA40] [57]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Mirtazapine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [14]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Ritodrine. Preterm labour/delivery [JB00] [27]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Degarelix. Prostate cancer [2C82] [24]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and ABIRATERONE. Prostate cancer [2C82] [24]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Nilutamide. Prostate cancer [2C82] [24]
Enzalutamide DMGL19D Moderate Increased metabolism of Mirtazapine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [21]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Flutamide. Prostate cancer [2C82] [24]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Relugolix. Prostate cancer [2C82] [24]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Bicalutamide. Prostate cancer [2C82] [24]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Mirtazapine caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [14]
Bosentan DMIOGBU Moderate Increased metabolism of Mirtazapine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [21]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Sorafenib. Renal cell carcinoma [2C90] [21]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [58]
Celecoxib DM6LOQU Moderate Decreased metabolism of Mirtazapine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [59]
Dexamethasone DMMWZET Moderate Increased metabolism of Mirtazapine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [21]
Nafcillin DMN9RPO Moderate Increased metabolism of Mirtazapine caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [21]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Quetiapine. Schizophrenia [6A20] [23]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Mirtazapine and Mesoridazine. Schizophrenia [6A20] [23]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Mirtazapine and Thioridazine. Schizophrenia [6A20] [23]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Mirtazapine and Iloperidone. Schizophrenia [6A20] [23]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Haloperidol. Schizophrenia [6A20] [23]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Mirtazapine and Amisulpride. Schizophrenia [6A20] [60]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Asenapine. Schizophrenia [6A20] [23]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Mirtazapine and Pimozide. Schizophrenia [6A20] [24]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Mirtazapine and Fentanyl. Sensation disturbance [MB40] [15]
Sufentanil DMU7YEL Major Additive serotonergic effects by the combination of Mirtazapine and Sufentanil. Sensation disturbance [MB40] [15]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Vardenafil. Sexual dysfunction [HA00-HA01] [21]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Mirtazapine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [14]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Mirtazapine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [24]
Larotrectinib DM26CQR Moderate Decreased metabolism of Mirtazapine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [14]
Armodafinil DMGB035 Moderate Increased metabolism of Mirtazapine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [21]
LEE011 DMMX75K Moderate Decreased metabolism of Mirtazapine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [14]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [21]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Mirtazapine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [23]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [24]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [21]
Pitolisant DM8RFNJ Moderate Increased metabolism of Mirtazapine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [24]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [21]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Adenosine. Supraventricular tachyarrhythmia [BC81] [23]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Mirtazapine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [61]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Lenvatinib. Thyroid cancer [2D10] [21]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Mirtazapine and Papaverine. Tonus and reflex abnormality [MB47] [62]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Mirtazapine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [63]
Enoxacin DMYTE6L Moderate Decreased metabolism of Mirtazapine caused by Enoxacin mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [14]
Elagolix DMB2C0E Moderate Increased metabolism of Mirtazapine caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [21]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Astemizole. Vasomotor/allergic rhinitis [CA08] [21]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [64]
Mexiletine DMCTE9R Moderate Decreased metabolism of Mirtazapine caused by Mexiletine mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [14]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Procainamide. Ventricular tachyarrhythmia [BC71] [23]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Propafenone. Ventricular tachyarrhythmia [BC71] [21]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Mirtazapine and Flecainide. Ventricular tachyarrhythmia [BC71] [21]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Mirtazapine and Amiodarone. Ventricular tachyarrhythmia [BC71] [23]
⏷ Show the Full List of 237 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Alpha-tocopherol E00243 14985 Antimicrobial preservative; Antioxidant
Aspartame E00402 134601 Flavoring agent
Caryophyllene E00471 5281515 Flavoring agent
Dimethyl benzyl carbinyl acetate E00196 9024 Adsorbent; Flavoring agent
Ethyl butyrate E00153 7762 Flavoring agent
FD&C blue no. 2 E00446 2723854 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Acetaldehyde E00003 177 Flavoring agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Xylitol E00136 6912 Coating agent; Diluent; Emollient; Flavoring agent; Humectant
⏷ Show the Full List of 34 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Mirtazapine 15 mg tablet 15 mg Disintegrating Oral Tablet Oral
Mirtazapine 30 mg tablet 30 mg Disintegrating Oral Tablet Oral
Mirtazapine 45 mg tablet 45 mg Disintegrating Oral Tablet Oral
Mirtazapine 15 mg tablet 15 mg Oral Tablet Oral
Mirtazapine 45 mg tablet 45 mg Oral Tablet Oral
Mirtazapine 30 mg tablet 30 mg Oral Tablet Oral
Mirtazapine 7.5 mg tablet 7.5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7241).
2 BDDCS applied to over 900 drugs
3 Timmer CJ, Sitsen JM, Delbressine LP: Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000 Jun;38(6):461-74. doi: 10.2165/00003088-200038060-00001.
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Bioavailability of mirtazapine from Remeron? tablets after single and multiple oral dosing
7 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
8 A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
9 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10 Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004 Dec;24(6):647-52.
11 Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
12 [Gynecomastia-galactorrhea during treatment with mirtazapine]. Presse Med. 2004 Apr 10;33(7):458. doi: 10.1016/s0755-4982(04)98631-9.
13 Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells. J Psychiatr Res. 2006 Jun;40(4):374-9. doi: 10.1016/j.jpsychires.2005.04.016. Epub 2005 Jul 5.
14 Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
15 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
16 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
17 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
18 Cerner Multum, Inc. "Australian Product Information.".
19 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
20 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
21 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
22 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
23 Canadian Pharmacists Association.
24 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
26 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
27 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
28 Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
29 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
30 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
31 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
33 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
34 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
35 Sitsen JM, Maris FA, Timmer CJ "Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects." Eur J Drug Metab Pharmacokinet 26 (2001): 109-21. [PMID: 11554425]
36 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
37 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
38 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
39 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
40 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
41 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
42 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
44 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
45 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
46 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
47 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
48 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
49 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
50 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
51 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
52 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
53 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
54 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
55 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
56 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
57 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
58 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
59 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
60 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
61 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
62 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
63 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
64 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.